TapewireFind a company

person · Reporting owner

FAVORITO TAMARA A

Disclosed activity across 4 companies

Tapewire entity
29284
SEC CIK
0001288232

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ARTELO BIOSCIENCES, INC.ARTL · Entity 8413DirectorJuly 17, 2026July 21, 2026
TuHURA Biosciences, Inc./NVKTRA · Entity 6601DirectorAugust 30, 2023September 01, 2023
Viridian Therapeutics, Inc.\DESGNL · Entity 4316CFO, Secretary, TreasurerOctober 31, 2016November 03, 2016
ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212DirectorJune 04, 2026June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARTELO BIOSCIENCES, INC.

Report date July 17, 2026 · Filed July 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-07-17Direct136 Reported balance After 2026-07-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-07-17 · Grant · Acquired 136 · Balance 136

F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

TuHURA Biosciences, Inc./NV

Report date August 30, 2023 · Filed September 01, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2033-08-30Direct8,500 Reported balance After 2023-08-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-08-30 · Grant · Acquired 8,500 · Balance 8,500

F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.

Viridian Therapeutics, Inc.\DE

Report date October 31, 2016 · Filed November 03, 2016

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Trust72,994 Reported balance After 2016-10-31 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2016-10-31 · Exercise / conversion · Acquired 46,000 · Balance 72,994

F1: Restricted stock units converted into common stock on a one-for-one basis.

Common StockSEC Table I · non-derivativeIndirectBy Trust52,027 Reported balance After 2016-10-31 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2016-10-31 · Tax withholding · Disposed 20,967 · Balance 52,027

F2: Shares withheld to satisfy tax withholding obligations.

Common StockSEC Table I · non-derivativeIndirectBy Trust152,027 Reported balance After 2016-10-31 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2016-10-31 · Exercise / conversion · Acquired 100,000 · Balance 152,027

F1: Restricted stock units converted into common stock on a one-for-one basis.

Common StockSEC Table I · non-derivativeIndirectBy Trust106,447 Reported balance After 2016-10-31 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2016-10-31 · Tax withholding · Disposed 45,580 · Balance 106,447

F2: Shares withheld to satisfy tax withholding obligations.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2016-10-31 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2016-10-31 · Exercise / conversion · Disposed 46,000 · Balance 0

F1: Restricted stock units converted into common stock on a one-for-one basis.

F3: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2016-10-31 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2016-10-31 · Exercise / conversion · Disposed 100,000 · Balance 0

F1: Restricted stock units converted into common stock on a one-for-one basis.

F4: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units converted into common stock on a one-for-one basis.

F2: Shares withheld to satisfy tax withholding obligations.

F3: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full.

F4: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full.

ZEVRA THERAPEUTICS, INC.

Report date June 04, 2026 · Filed June 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2036-06-03Direct30,000 Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-04 · Grant · Acquired 30,000 · Balance 30,000

F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 17, 2026 Filed Jul 21, 2026 22:24 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 136 $0.00 Strike: $1.15 $0.00
Disclosure

SEC source: 0001640334-26-001221 · form4.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136

Underlying: Common Stock · 136 shares

Expires 2036-07-17

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

Read SEC document
June 04, 2026 Filed Jun 18, 2026 20:16 UTC ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $11.17 $0.00
Disclosure

SEC source: 0001434647-26-000055 · wk-form4_1781813796.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-03

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Read SEC document
January 30, 2026 Filed Feb 2, 2026 21:45 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Options (right to buy) · Derivative 292 $0.00 Strike: $1.71 $0.00
Disclosure

SEC source: 0001640334-26-000195 · form4.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 292

Underlying: Common Stock · 292 shares

Expires 2036-01-30

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026.

Read SEC document
October 28, 2025 Filed Oct 31, 2025 01:28 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 ConversionConvertible Promissory Note · Derivative Not disclosed $19,793.00 Strike: $3.40 $19,793.00
Disclosure

SEC source: 0001640334-25-001923 · form4.xml · derivative · entry 4

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2026-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

F1 · derivative.underlying_shares: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · derivative.underlying_shares: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Read SEC document
October 28, 2025 Filed Oct 31, 2025 01:28 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 ConversionWarrant (right to buy) · Derivative 12,566 Not disclosed Strike: $3.40 Not disclosed
Disclosure

SEC source: 0001640334-25-001923 · form4.xml · derivative · entry 3

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,566

Underlying: Common Stock · 12,566 shares

Expires 2030-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

F1 · price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Read SEC document
October 28, 2025 Filed Oct 31, 2025 01:28 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 ConversionWarrant (right to buy) · Derivative 6,846 Not disclosed Strike: $6.24 Not disclosed
Disclosure

SEC source: 0001640334-25-001923 · form4.xml · derivative · entry 2

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,846

Underlying: Common Stock · 6,846 shares

Expires 2030-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

F2 · price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

F1 · price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

Read SEC document
October 28, 2025 Filed Oct 31, 2025 01:28 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 ConversionConvertible Promissory Note · Derivative Not disclosed $25,000.00 $25,000.00
Disclosure

SEC source: 0001640334-25-001923 · form4.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · derivative.exercise_price: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

F1 · kind: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · kind: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

F1 · derivative.underlying_shares: Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

F2 · derivative.underlying_shares: On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Read SEC document
September 12, 2025 Filed Sep 16, 2025 20:15 UTC ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 PurchaseCommon Stock 3,175 $7.79 $24,718.01
Disclosure

SEC source: 0001288232-25-000009 · wk-form4_1758053735.xml · nonDerivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,894

Read SEC document
May 29, 2025 Filed May 31, 2025 01:39 UTC ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $8.62 $0.00
Disclosure

SEC source: 0001437749-25-019047 · rdgdoc.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-05-28

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025.

F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Read SEC document
May 01, 2025 Filed May 5, 2025 21:24 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 PurchaseConvertible Promissory Note · Derivative Not disclosed $25,000.00 $25,000.00
Disclosure

SEC source: 0001640334-25-000789 · form4.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By trust

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2025-10-28

F1 · derivative.exercise_price: On or about May 1, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") with the Reporting Person, pursuant to which the Issuer issued a convertible note (the "Note") to the Reporting Person. The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Note). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable on October 28, 2025 (the "Maturity Date").

F2 · derivative.exercise_price: At the Maturity Date, the Reporting Person may (at the Reporting Person's sole option) convert all of that certain unpaid portion of principal and accrued interest of the Reporting Person's Note into shares of the Issuer's common stock ("Common Stock") (the "Voluntary Conversion"), specifically into that number of shares of Common Stock (the "Converted Shares") equal to the unpaid principal balance and any accrued interest of each Note divided by $1.29. The amount of principal balance and any accrued interest of the Note convertible pursuant to the Voluntary Conversion shall be the number of Converted Shares multiplied by $1.04 (the "Minimum Price"). Should the Reporting Person not elect Voluntary Conversion, such portion of the unpaid principal balance and any accrued interest of the Note subject to Voluntary Conversion shall be immediately due and payable in cash.

F3 · derivative.exercise_price: At the Maturity Date, that portion of the unpaid principal balance and any accrued interest of the Note not subject to the Voluntary Conversion shall be automatically converted into a warrant to purchase shares of the Issuer's Common Stock (the "Warrant") at a conversion price of $0.125 per share issuable pursuant to the Warrant (the "Automatic Conversion"). The exercise price of such Warrant for each Warrant Share shall be equal to the Minimum Price.

F1 · derivative.underlying_shares: On or about May 1, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") with the Reporting Person, pursuant to which the Issuer issued a convertible note (the "Note") to the Reporting Person. The Notes will accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default (as defined in the Note). All unpaid principal, together with any then unpaid and accrued interest and other amounts payable thereunder, shall be due and payable on October 28, 2025 (the "Maturity Date").

F2 · derivative.underlying_shares: At the Maturity Date, the Reporting Person may (at the Reporting Person's sole option) convert all of that certain unpaid portion of principal and accrued interest of the Reporting Person's Note into shares of the Issuer's common stock ("Common Stock") (the "Voluntary Conversion"), specifically into that number of shares of Common Stock (the "Converted Shares") equal to the unpaid principal balance and any accrued interest of each Note divided by $1.29. The amount of principal balance and any accrued interest of the Note convertible pursuant to the Voluntary Conversion shall be the number of Converted Shares multiplied by $1.04 (the "Minimum Price"). Should the Reporting Person not elect Voluntary Conversion, such portion of the unpaid principal balance and any accrued interest of the Note subject to Voluntary Conversion shall be immediately due and payable in cash.

F3 · derivative.underlying_shares: At the Maturity Date, that portion of the unpaid principal balance and any accrued interest of the Note not subject to the Voluntary Conversion shall be automatically converted into a warrant to purchase shares of the Issuer's Common Stock (the "Warrant") at a conversion price of $0.125 per share issuable pursuant to the Warrant (the "Automatic Conversion"). The exercise price of such Warrant for each Warrant Share shall be equal to the Minimum Price.

Read SEC document
December 20, 2024 Filed Dec 23, 2024 21:00 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 1,750 $0.00 Strike: $0.95 $0.00
Disclosure

SEC source: 0001640334-24-001925 · form4.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires 2034-12-20

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean December 20, 2024.

Read SEC document
May 13, 2024 Filed May 16, 2024 01:20 UTC ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 GrantStock Option (right to buy) · Derivative 49,200 $0.00 Strike: $4.89 $0.00
Disclosure

SEC source: 0001437749-24-017182 · rdgdoc.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,200

Underlying: Common Stock · 49,200 shares

Expires 2034-05-12

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024.

F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 1,083 Not disclosed Strike: $1.55 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 10

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,083

Underlying: Common Stock · 1,083 shares

Expires 2033-08-04

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 667 Not disclosed Strike: $1.55 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 9

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 667

Underlying: Common Stock · 667 shares

Expires 2033-06-30

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 667 Not disclosed Strike: $1.55 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 8

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 667

Underlying: Common Stock · 667 shares

Expires 2032-06-24

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 667 Not disclosed Strike: $1.55 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 7

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 667

Underlying: Common Stock · 667 shares

Expires 2031-07-16

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 2,000 Not disclosed Strike: $1.55 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 6

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires 2031-03-05

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F8 · derivative.exercise_date: Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 Disposition to issuerStock Option (right to buy) · Derivative 1,083 Not disclosed Strike: $2.01 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 5

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,083 shares

Expires 2033-08-04

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F7 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 Disposition to issuerStock Option (right to buy) · Derivative 667 Not disclosed Strike: $1.99 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 4

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 667 shares

Expires 2033-06-30

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F6 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 Disposition to issuerStock Option (right to buy) · Derivative 667 Not disclosed Strike: $4.89 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 3

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 667 shares

Expires 2032-06-24

F5 · derivative.exercise_price: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F5 · derivative.underlying_shares: This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 Disposition to issuerStock Option (right to buy) · Derivative 667 Not disclosed Strike: $15.00 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 2

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 667 shares

Expires 2031-07-16

F4 · derivative.exercise_price: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F4 · derivative.underlying_shares: This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.

Read SEC document
February 28, 2024 Filed Mar 2, 2024 01:53 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 Disposition to issuerStock Option (right to buy) · Derivative 2,000 Not disclosed Strike: $22.80 Not disclosed
Disclosure

SEC source: 0001640334-24-000335 · primary_doc.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,000 shares

Expires 2031-03-05

F1 · derivative.exercise_price: This option was granted on March 5, 2021 and was previously reported as covering 30,000 shares at an exercise price of $1.52 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.

F3 · price: The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).

F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the two (2) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the three (3) year anniversary of the Vesting Commencement Date, such that the option shall be fully vested on the three (3) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 5, 2021.

F1 · derivative.underlying_shares: This option was granted on March 5, 2021 and was previously reported as covering 30,000 shares at an exercise price of $1.52 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.

Read SEC document
August 30, 2023 Filed Sep 1, 2023 22:00 UTC TuHURA Biosciences, Inc./NV KTRA · Entity 6601 GrantOptions (Right to Buy) · Derivative 8,500 $0.00 Strike: $4.66 $0.00
Disclosure

SEC source: 0001493152-23-031535 · ownership.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2033-08-30

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.

Read SEC document
August 04, 2023 Filed Aug 8, 2023 20:54 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 1,083 $0.00 Strike: $2.01 $0.00
Disclosure

SEC source: 0001640334-23-001482 · form4.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,083

Underlying: Common Stock · 1,083 shares

Expires 2033-08-04

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023.

Read SEC document
June 30, 2023 Filed Jul 3, 2023 18:05 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 667 $0.00 Strike: $2.01 $0.00
Disclosure

SEC source: 0001640334-23-001201 · form4.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 667

Underlying: Common Stock · 667 shares

Expires 2033-06-30

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023.

Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:33 UTC ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0001437749-23-016494 · rdgdoc.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-30

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 31, 2023.

F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Read SEC document
April 25, 2023 Filed May 9, 2023 01:51 UTC ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 GrantStock Option (right to buy) · Derivative 39,200 $0.00 Strike: $5.59 $0.00
Disclosure

SEC source: 0001437749-23-013124 · rdgdoc.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,200

Underlying: Common Stock · 39,200 shares

Expires 2033-04-24

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023.

F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Read SEC document
March 17, 2023 Filed Mar 21, 2023 20:32 UTC ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 PurchaseCommon Stock 519 $4.82 $2,502.36
Disclosure

SEC source: 0001437749-23-007397 · rdgdoc.xml · nonDerivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 719

Read SEC document
July 01, 2022 Filed Jul 5, 2022 20:05 UTC TuHURA Biosciences, Inc./NV KTRA · Entity 6601 GrantOptions (Right to Buy) · Derivative 100,000 $0.00 Strike: $0.26 $0.00
Disclosure

SEC source: 0001493152-22-018529 · ownership.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-07-01

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022.

Read SEC document
June 28, 2022 Filed Jun 30, 2022 21:19 UTC ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $4.52 $0.00
Disclosure

SEC source: 0001437749-22-016300 · rdgdoc.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-27

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 28, 2022.

F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's seventh amended and restated non-employee director compensation policy.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.

Read SEC document
June 24, 2022 Filed Jun 27, 2022 21:17 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $0.33 $0.00
Disclosure

SEC source: 0001640334-22-001357 · form4.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-06-24

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 24, 2022.

Read SEC document
May 20, 2022 Filed May 25, 2022 00:58 UTC ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 PurchaseCommon Stock 200 $4.87 $974.00
Disclosure

SEC source: 0001437749-22-013468 · rdgdoc.xml · nonDerivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

Read SEC document
September 22, 2021 Filed Sep 23, 2021 00:37 UTC TuHURA Biosciences, Inc./NV KTRA · Entity 6601 GrantOptions (Right to Buy) · Derivative 35,000 $0.00 Strike: $1.24 $0.00
Disclosure

SEC source: 0000905718-21-001223 · kintara_fm4sep222021.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2031-09-22

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.

Read SEC document
July 16, 2021 Filed Jul 26, 2021 20:22 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001640334-21-001675 · form4.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-07-16

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 16, 2021.

Read SEC document
April 29, 2021 Filed May 3, 2021 20:34 UTC TuHURA Biosciences, Inc./NV KTRA · Entity 6601 GrantOptions (Right to Grant) · Derivative 75,000 $0.00 Strike: $1.37 $0.00
Disclosure

SEC source: 0000905718-21-000652 · kintara_fm4apr292021.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-04-29

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, one-third of the options vest on April 29, 2022, with the remaining options vesting in eight equal quarterly installments commencing on July 29, 2022.

Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:24 UTC ARTELO BIOSCIENCES, INC. ARTL · Entity 8413 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $1.52 $0.00
Disclosure

SEC source: 0001640334-21-000542 · form4.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-03-05

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the two (2) year anniversary of the Vesting Commencement Date, one third (1/3rd) of the shares subject to the option shall vest on the three (3) year anniversary of the Vesting Commencement Date, such that the option shall be fully vested on the three (3) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 5, 2021.

Read SEC document
October 31, 2016 Filed Nov 3, 2016 00:39 UTC Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 Exercise / conversionRestricted Stock Units · Derivative 100,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-16-148045 · doc4.xml · derivative · entry 6

SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full.

F4 · derivative.expiration_date: On March 28, 2016, the reporting person was granted 100,000 restricted stock units. In connection with the execution of the Merger Agreement, the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of these restricted stock units in full.

Read SEC document
October 31, 2016 Filed Nov 3, 2016 00:39 UTC Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 Exercise / conversionRestricted Stock Units · Derivative 46,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-16-148045 · doc4.xml · derivative · entry 5

SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full.

F3 · derivative.expiration_date: On August 4, 2014, the reporting person was granted 92,000 restricted stock units. In connection with the execution of the Agreement and Plan of Merger and Reorganization, dated October 31, 2016, by and among Signal Genetics, Inc. (the "Issuer"), Signal Merger Sub, Inc. and Miragen Therapeutics, Inc. (the "Merger Agreement"), the Compensation Committee of the Issuer's Board of Directors accelerated the vesting of the remaining 46,000 restricted stock units in full.

Read SEC document
October 31, 2016 Filed Nov 3, 2016 00:39 UTC Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 Tax withholdingCommon Stock 45,580 $0.36 $16,408.80
Disclosure

SEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 4

SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 106,447

F2 · shares: Shares withheld to satisfy tax withholding obligations.

Read SEC document
October 31, 2016 Filed Nov 3, 2016 00:39 UTC Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 Exercise / conversionCommon Stock 100,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 3

SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 152,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units converted into common stock on a one-for-one basis.

Read SEC document
October 31, 2016 Filed Nov 3, 2016 00:39 UTC Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 Tax withholdingCommon Stock 20,967 $0.36 $7,548.12
Disclosure

SEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 2

SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 52,027

F2 · shares: Shares withheld to satisfy tax withholding obligations.

Read SEC document
October 31, 2016 Filed Nov 3, 2016 00:39 UTC Viridian Therapeutics, Inc.\DE SGNL · Entity 4316 Exercise / conversionCommon Stock 46,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-16-148045 · doc4.xml · nonDerivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · CFO, Secretary, Treasurer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 72,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units converted into common stock on a one-for-one basis.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.